Abstract
Background: The most potent angiogenic factor is the vascular endothelial growth factor (VEGF), and CD34 is an endothelial antigen that has been used to highlight the microvasculature vessel density (MVD) as a direct marker of the degree of neoangiogenesis. In the present study we report that VEGF expression and its relationship with MVD, in poorly and well differentiated colon adenocarcinoma, in order to consider the possibility of using the correlation between both antibodies as a prognostic factor. Materials and Methods: Tumor sections were stained by immunohistochemistry for CD34 and VEGF. Results: The mean of VEGF and CD34 did not show any significant differences between both types of tumors. Conclusion: The conventional factors taken into consideration were not significantly related to the angiogenic factors examined, so we could affirm that the correlation of both markers could be useful as prognostic factor.
Keywords: Colon cancer, VEGF, CD34, angiogenesis, colon, adenocarcinoma
Current Chemical Biology
Title: Evaluation of Angiogenesis with the Expression of VEGF-C and CD34 in Human Colon Cancer
Volume: 3 Issue: 3
Author(s): Ana Maria Inda, Marcela Nilda Garcia, Laura Beatriz Andrini, Adriana Laura Garcia, Ayelen Fernandez Blanco, Cecilia Cristina Furnus, Susana Mercedes Galletti, Javier Brandoni, Jorge Guillermo Martinez, Guillermo Daniel Prat and Ana Lia Errecalde
Affiliation:
Keywords: Colon cancer, VEGF, CD34, angiogenesis, colon, adenocarcinoma
Abstract: Background: The most potent angiogenic factor is the vascular endothelial growth factor (VEGF), and CD34 is an endothelial antigen that has been used to highlight the microvasculature vessel density (MVD) as a direct marker of the degree of neoangiogenesis. In the present study we report that VEGF expression and its relationship with MVD, in poorly and well differentiated colon adenocarcinoma, in order to consider the possibility of using the correlation between both antibodies as a prognostic factor. Materials and Methods: Tumor sections were stained by immunohistochemistry for CD34 and VEGF. Results: The mean of VEGF and CD34 did not show any significant differences between both types of tumors. Conclusion: The conventional factors taken into consideration were not significantly related to the angiogenic factors examined, so we could affirm that the correlation of both markers could be useful as prognostic factor.
Export Options
About this article
Cite this article as:
Inda Maria Ana, Garcia Nilda Marcela, Andrini Beatriz Laura, Garcia Laura Adriana, Blanco Fernandez Ayelen, Furnus Cristina Cecilia, Galletti Mercedes Susana, Brandoni Javier, Martinez Guillermo Jorge, Prat Daniel Guillermo and Errecalde Lia Ana, Evaluation of Angiogenesis with the Expression of VEGF-C and CD34 in Human Colon Cancer, Current Chemical Biology 2009; 3 (3) . https://dx.doi.org/10.2174/2212796810903030302
DOI https://dx.doi.org/10.2174/2212796810903030302 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Studies and Biological Aspects of Substantial Indole Derivatives with Anti-cancer Activity
Current Organic Chemistry Recent Patents on Cell Cycle Regulatory Proteins
Recent Patents on Biotechnology Diffusion-Weighted MRI for Assessment of Early Cancer Treatment Response
Current Pharmaceutical Biotechnology Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Current Drug Targets Efficacy and Safety of Combined Radiotherapy with EGFR Inhibitors and Chemotherapy for Laryngeal Organ Preservation in Patients with Locally Advanced Hypopharyngeal Carcinomas
Current Cancer Drug Targets The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer
Current Clinical Pharmacology Lipid Based Nanoparticles as Inherent Reversing Agents of Multidrug Resistance in Cancer
Current Pharmaceutical Design Combining Cytotoxic and Immune-Mediated Gene Therapy to Treat Brain Tumors
Current Topics in Medicinal Chemistry MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design The Significance of Transferrin Receptors in Oncology: the Development of Functional Nano-based Drug Delivery Systems
Current Drug Delivery Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers
Anti-Cancer Agents in Medicinal Chemistry Editorial (Mini Thematic Issue: Immunotherapy – A Pivotal Mechanism in the Fight of Cancer)
Reviews on Recent Clinical Trials CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design Gene Therapy and Biologic Therapy with Interleukin?4
Current Gene Therapy Basal Breast Cancer: A Complex and Deadly Molecular Subtype
Current Molecular Medicine Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma
Current Medicinal Chemistry Microsphere Based Improved Sunscreen Formulation of Ethylhexyl Methoxycinnamate
Current Drug Delivery HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Morin Inhibits Ovarian Cancer Growth through the Inhibition of NF-κB Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry